Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome
Series A financing co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors Rugonersen, a potentially best-in-class antisense oligonucleotide (ASO) therapy for Angelman syndrome, is expected to enter a Phase 3 clinical study in mid-2026 Doug Fambrough, Rich Gaster, and Sandeep Kulkarni join board of directors CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) — Oak […]